Summary: Merck & Co., Inc. provides an update on their strong performance and pipeline progress during the Bank of America Global Healthcare Conference. They have shown growth in the second quarter and raised their full-year guidance.
Full articleSummary: Wells Fargo named Eli Lilly & Co. as its new top pick among large-cap pharmaceutical stocks, highlighting its potential for significant upside and strong pipeline.
Full articleSummary: The report '2024 Perceptions in Environmental Sustainability in the Life Sciences' has been added to ResearchAndMarkets.com's offering. It details findings of research exploring trends in customers' perceptions and expectations of environmental sustainability in the life sciences industry.
Full articleSummary: Merck gains U.S. regulatory approval for Capvaxive pneumococcal vaccine, set to compete with Pfizer's Prevnar 20. Merck expects to provide broader protection compared to existing vaccines, with expected availability in late 2024. Pfizer remains confident with its 98% market share in the adult pneumococcal vaccine segment.
Full articleSummary: FDA has a busy week ahead with six target action dates. Merck awaiting verdict on pneumococcal shot, Argenx seeks approval for Vyvgart Hytrulo in CIDP, BMS targets Krazati expansion into CRC among other drug applications.
Full articleSummary: Stock market indexes remained lower today amidst growing concerns of inflation ahead of a key Fed report, impacting major indexes and sectors like health care. The Dow Jones and S&P 500 declined, while the Nasdaq had a slightly better performance. Yield on the 10-year Treasury note jumped, leading to worries about potential rate cuts being pushed back. Companies such as Tesla, C3.ai, UnitedHealth Group, and Salesforce experienced stock movements related to earnings, acquisitions, or market sentiment.
Full articleSummary: J&J and Merck are making billion-dollar deals to acquire rights to experimental treatments, with J&J acquiring a skin disorder treatment for $1.25 billion and Merck nearing a $1.3 billion deal for EyeBio. Insmed Incorporated's lung disease drug sees success in a Phase 3 trial, resulting in a surge in share price.
Full articleSummary: Dow Jones futures and major indices were little changed ahead of the stock market open. Artificial intelligence stock Palo Alto Networks plunged more than 9% on earnings, while Nvidia earnings and Federal Reserve minutes are due later this week. Other key earnings movers include Zoom Video Communications. Current economic reports include existing-home and new-home sales, and PMI data. JPMorgan Chase, Merck, Apple, and Microsoft are among notable stocks.
Full articleSummary: The Dow Jones Industrial Average dropped while other major indexes rose as Wall Street seeks more record highs. Among the gainers was Nvidia after analysts raised its price target, while Li Auto tumbled due to an earnings miss. The 10-year Treasury yield ticked higher and oil prices dipped. Investors are awaiting the release of Federal Reserve minutes this week.
Full articleSummary: Washington Federal Bank, a subsidiary of WaFd, is selling commercial multi-family real estate loans to Bank of America for $2.9 billion to reduce exposure in a troubled sector. The commercial real estate sector has been challenged by higher borrowing costs and lower occupancy rates, causing concern among investors and regulators.
Full articleSummary: Broadcom, Merck & Co., and Airbnb are among the top stocks featured in the Zacks Analyst Blog. Broadcom expects strong revenue growth in fiscal 2024, especially in AI and networking segments. Merck is experiencing growth driven by products like Keytruda, but faces challenges in generic competition and competitive pressures. Airbnb's positive trend in Gross Booking Value and strong momentum in app downloads are positives, but it faces volatility in travel demand and competition in the online travel space.
Full articleSummary: Pfizer to pay $250 million to settle over 10,000 lawsuits related to Zantac, a heartburn drug linked to cancer risk, with ongoing discussions and legal battles among pharmaceutical companies related to the drug's liability.
Full article